DK1879623T3 - Genterapi til rygmarvssygdomme - Google Patents

Genterapi til rygmarvssygdomme

Info

Publication number
DK1879623T3
DK1879623T3 DK06752135.1T DK06752135T DK1879623T3 DK 1879623 T3 DK1879623 T3 DK 1879623T3 DK 06752135 T DK06752135 T DK 06752135T DK 1879623 T3 DK1879623 T3 DK 1879623T3
Authority
DK
Denmark
Prior art keywords
genterapy
background diseases
diseases
background
Prior art date
Application number
DK06752135.1T
Other languages
English (en)
Inventor
Seng Cheng
James Dodge
Lamya Shihabuddin
Marco Passini
Catherine R O'riordan
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Application granted granted Critical
Publication of DK1879623T3 publication Critical patent/DK1879623T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
    • C12N15/8645—Adeno-associated virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK06752135.1T 2005-05-02 2006-05-02 Genterapi til rygmarvssygdomme DK1879623T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67721305P 2005-05-02 2005-05-02
US79021706P 2006-04-08 2006-04-08
PCT/US2006/016943 WO2006119341A2 (en) 2005-05-02 2006-05-02 Gene therapy for spinal cord disorders

Publications (1)

Publication Number Publication Date
DK1879623T3 true DK1879623T3 (da) 2012-12-17

Family

ID=37308661

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06752135.1T DK1879623T3 (da) 2005-05-02 2006-05-02 Genterapi til rygmarvssygdomme

Country Status (14)

Country Link
US (2) US10744210B2 (da)
EP (1) EP1879623B1 (da)
JP (5) JP5766389B2 (da)
CN (1) CN105770909A (da)
AU (1) AU2006242129A1 (da)
BR (1) BRPI0611540A2 (da)
CA (1) CA2606490C (da)
DK (1) DK1879623T3 (da)
ES (1) ES2394482T3 (da)
IL (2) IL187023A (da)
MX (1) MX2007013734A (da)
PL (1) PL1879623T3 (da)
PT (1) PT1879623E (da)
WO (1) WO2006119341A2 (da)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2607173C (en) 2005-05-02 2018-04-24 Genzyme Corporation Composition comprising an adeno-associated virus vector having a serotype 1 capsid for use in treating lysosomal storage diseases or alzheimer's disease
PT1879623E (pt) 2005-05-02 2012-12-20 Genzyme Corp Terapia génica para distúrbios da medula espinal
EP2465925A1 (en) 2005-07-22 2012-06-20 The Board Of Trustees Of The Leland Light-activated cation channel and uses thereof
US10052497B2 (en) * 2005-07-22 2018-08-21 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
US8926959B2 (en) 2005-07-22 2015-01-06 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
US9274099B2 (en) 2005-07-22 2016-03-01 The Board Of Trustees Of The Leland Stanford Junior University Screening test drugs to identify their effects on cell membrane voltage-gated ion channel
US9238150B2 (en) 2005-07-22 2016-01-19 The Board Of Trustees Of The Leland Stanford Junior University Optical tissue interface method and apparatus for stimulating cells
HUE031156T2 (en) 2006-06-07 2017-06-28 Genzyme Corp Gene therapy for amyotrophic lateral sclerosis and other spinal cord diseases
US8398692B2 (en) 2007-01-10 2013-03-19 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
US8401609B2 (en) 2007-02-14 2013-03-19 The Board Of Trustees Of The Leland Stanford Junior University System, method and applications involving identification of biological circuits such as neurological characteristics
WO2008106694A2 (en) 2007-03-01 2008-09-04 The Board Of Trustees Of The Leland Stanford Junior University Systems, methods and compositions for optical stimulation of target cells
EP2019143A1 (en) * 2007-07-23 2009-01-28 Genethon CNS gene delivery using peripheral administration of AAV vectors
EP2058401A1 (en) 2007-10-05 2009-05-13 Genethon Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
US10434327B2 (en) * 2007-10-31 2019-10-08 The Board Of Trustees Of The Leland Stanford Junior University Implantable optical stimulators
US10035027B2 (en) * 2007-10-31 2018-07-31 The Board Of Trustees Of The Leland Stanford Junior University Device and method for ultrasonic neuromodulation via stereotactic frame based technique
ES2701349T3 (es) 2008-04-23 2019-02-21 Univ Leland Stanford Junior Sistemas, métodos y composiciones para la estimulación óptica de células diana
MX2010012986A (es) 2008-05-29 2011-05-25 Univ Leland Stanford Junior Linea de celulas, sistema y metodo para control optico de mensajeros secundarios.
MY156389A (en) * 2008-06-17 2016-02-15 Univ Leland Stanford Junior Methods, systems and devices for optical stimulation of target cells using an optical transmission element
SG191604A1 (en) 2008-06-17 2013-07-31 Univ Leland Stanford Junior Apparatus and methods for controlling cellular development
US9101759B2 (en) 2008-07-08 2015-08-11 The Board Of Trustees Of The Leland Stanford Junior University Materials and approaches for optical stimulation of the peripheral nervous system
NZ602416A (en) 2008-11-14 2014-08-29 Univ Leland Stanford Junior Optically-based stimulation of target cells and modifications thereto
CN102459611B (zh) 2009-05-02 2016-11-09 建新公司 神经退行性疾病的基因治疗
US9079940B2 (en) 2010-03-17 2015-07-14 The Board Of Trustees Of The Leland Stanford Junior University Light-sensitive ion-passing molecules
CA2816971A1 (en) 2010-11-05 2012-05-10 The Board Of Trustees Of The Leland Stanford Junior University Light-activated chimeric opsins and methods of using the same
ES2661093T3 (es) 2010-11-05 2018-03-27 The Board Of Trustees Of The University Of The Leland Stanford Junior University Control y caracterización de la función de la memoria
CN106106368A (zh) 2010-11-05 2016-11-16 斯坦福大学托管董事会 光控cns功能障碍
CA2816976C (en) 2010-11-05 2019-12-03 The Board Of Trustees Of The Leland Standford Junior University Optogenetic control of reward-related behaviors
JP6145043B2 (ja) 2010-11-05 2017-06-07 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 光遺伝的方法で使用するための光の上方変換
CA2816990A1 (en) 2010-11-05 2012-05-10 The Board Of Trustees Of The Leland Stanford Junior University Stabilized step function opsin proteins and methods of using the same
US8696722B2 (en) 2010-11-22 2014-04-15 The Board Of Trustees Of The Leland Stanford Junior University Optogenetic magnetic resonance imaging
US20130164367A1 (en) * 2011-12-08 2013-06-27 The Board Of Regents Of The University Of Texas System Treatment of neurodegenerative disease with creb-binding protein
CN107936097A (zh) 2011-12-16 2018-04-20 斯坦福大学托管董事会 视蛋白多肽及其使用方法
EP3205374B1 (en) 2012-02-21 2019-03-27 The Board of Trustees of The Leland Stanford Junior University Compositions for treating neurogenic disorders of the pelvic floor
CN112574964A (zh) * 2012-05-18 2021-03-30 衣阿华大学研究基金会 用于治疗淀粉状蛋白沉积的方法和组合物
US9636380B2 (en) 2013-03-15 2017-05-02 The Board Of Trustees Of The Leland Stanford Junior University Optogenetic control of inputs to the ventral tegmental area
ES2742492T3 (es) 2013-03-15 2020-02-14 Univ Leland Stanford Junior Control optogenético del estado conductual
AU2014260101B2 (en) 2013-04-29 2018-07-26 Humboldt-Universitat Zu Berlin Devices, systems and methods for optogenetic modulation of action potentials in target cells
US10821154B2 (en) 2013-05-01 2020-11-03 Genzyme Corporation Compositions and methods for treating spinal muscular atrophy
GB201308917D0 (en) 2013-05-17 2013-07-03 Renishaw Plc Delivery
EP3033427A4 (en) 2013-08-14 2017-05-31 The Board Of Trustees Of The University Of the Leland Stanford Junior University Compositions and methods for controlling pain
US10568516B2 (en) 2015-06-22 2020-02-25 The Board Of Trustees Of The Leland Stanford Junior University Methods and devices for imaging and/or optogenetic control of light-responsive neurons
US11294165B2 (en) 2017-03-30 2022-04-05 The Board Of Trustees Of The Leland Stanford Junior University Modular, electro-optical device for increasing the imaging field of view using time-sequential capture
CA3109159A1 (en) * 2017-08-16 2019-02-21 Lgv1 S.R.L. Vtft isoform of a bpifb4 protein for use in neuronal diseases and injuries
CN113755524B (zh) * 2020-06-02 2023-11-03 舒泰神（北京）生物制药股份有限公司 用于治疗脊髓性肌萎缩的腺相关病毒载体及其用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4025A (en) * 1845-05-01 Feinting press
SE8303626D0 (sv) 1983-06-23 1983-06-23 Kabigen Ab A recombinant plasmid a transformant microorganism, a polydoxyrebonucleotide segment, a process for producing a biologically active protein, and the protein thus produced
US5672344A (en) * 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
US5773278A (en) 1991-05-03 1998-06-30 Mount Sinai Medical Center Acid sphingomyelinase gene
DE69434486T2 (de) 1993-06-24 2006-07-06 Advec Inc. Adenovirus vektoren für gentherapie
ES2328585T3 (es) 1993-10-25 2009-11-16 Canji, Inc. Vector de adenovirus recombinante y metodo de utilizacion.
PT733103E (pt) * 1993-11-09 2004-07-30 Targeted Genetics Corp Criacao de elevados titulos de vectores de aav recombinantes
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
EP0755454B1 (en) * 1994-04-13 2008-02-13 The Rockefeller University Aav-mediated delivery of dna to cells of the nervous system
AU1525797A (en) * 1996-04-22 1997-11-12 Medtronic, Inc. Two-stage angled venous cannula
US6544785B1 (en) * 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
AU1775901A (en) 1999-11-17 2001-05-30 Avigen, Inc. Recombinant adeno-associated virus virions for the treatment of lysosomal disorders
US20030165481A1 (en) 2000-02-24 2003-09-04 Hersh Louis B. Amyloid peptide inactivating enzyme to treat Alzheimer's disease
ES2252293T3 (es) * 2000-09-18 2006-05-16 Genzyme Corporation Vectores de expresion que contienene promotores hibridos de ubiquitina.
US20030050273A1 (en) 2001-08-29 2003-03-13 Keiya Ozawa Compositions and methods for treating neurodegenerative diseases
EP1453547B1 (en) * 2001-12-17 2016-09-21 The Trustees Of The University Of Pennsylvania Adeno-associated virus (aav) serotype 8 sequences, vectors containing same, and uses therefor
JP2005514403A (ja) 2001-12-21 2005-05-19 ザ ソーク インスティテュート フォー バイオロジカル スタディーズ 運動ニューロンに対する標的化逆行性遺伝子送達
US6998118B2 (en) * 2001-12-21 2006-02-14 The Salk Institute For Biological Studies Targeted retrograde gene delivery for neuronal protection
EP2269658B1 (en) 2003-05-01 2018-12-19 Genzyme Corporation Gene therapy for neurometabolic disorders
US20040258666A1 (en) * 2003-05-01 2004-12-23 Passini Marco A. Gene therapy for neurometabolic disorders
EP1716870A1 (en) 2005-04-29 2006-11-02 Bracco Imaging S.p.A. MRI contrast agents endowed with concentration independent responsiveness
CA2607173C (en) * 2005-05-02 2018-04-24 Genzyme Corporation Composition comprising an adeno-associated virus vector having a serotype 1 capsid for use in treating lysosomal storage diseases or alzheimer's disease
PT1879623E (pt) 2005-05-02 2012-12-20 Genzyme Corp Terapia génica para distúrbios da medula espinal
LT1986661T (lt) 2006-02-08 2018-12-10 Genzyme Corporation Nimano-piko a tipo ligos genų terapija

Also Published As

Publication number Publication date
JP6887008B2 (ja) 2021-06-16
IL187023A (en) 2015-10-29
WO2006119341A2 (en) 2006-11-09
IL187023A0 (en) 2008-02-09
IL237658A0 (en) 2015-04-30
WO2006119341A3 (en) 2007-06-28
US10744210B2 (en) 2020-08-18
CA2606490A1 (en) 2006-11-09
PL1879623T3 (pl) 2013-03-29
CA2606490C (en) 2018-02-06
EP1879623A4 (en) 2009-03-25
JP2017132774A (ja) 2017-08-03
US20210008227A1 (en) 2021-01-14
JP2013082731A (ja) 2013-05-09
JP2015163613A (ja) 2015-09-10
MX2007013734A (es) 2008-03-14
US20090069261A1 (en) 2009-03-12
CN105770909A (zh) 2016-07-20
JP2020050660A (ja) 2020-04-02
PT1879623E (pt) 2012-12-20
EP1879623B1 (en) 2012-10-03
EP1879623A2 (en) 2008-01-23
ES2394482T3 (es) 2013-02-01
JP2008540435A (ja) 2008-11-20
JP5766389B2 (ja) 2015-08-19
AU2006242129A1 (en) 2006-11-09
BRPI0611540A2 (pt) 2010-09-21

Similar Documents

Publication Publication Date Title
DK1879623T3 (da) Genterapi til rygmarvssygdomme
DK3424932T3 (da) Bronophthalider til terapeutisk anvendelse
DK1928882T3 (da) (s)-n-methylnaltrexon
ATE408603T1 (de) Pyrazolylcarboxanilide
CR9974A (es) Gavión
DE602006008259D1 (de) Siloxaneinkapselungen
DE502006003394D1 (de) Lehnenklappung
DE502006008475D1 (de) Wasserpumpenflügelrad
ATE549324T1 (de) Tetrahydrobenzoxazine
DE502006006857D1 (de) Wingungserregern
DE502006005768D1 (de) Hydrolysestabilisatorformulierungen
DE112006002964A5 (de) Zweirichtungsreflektanzverteilungsmessgerät
DE502005005839D1 (de) Feldgeerät
DE502006001397D1 (de) Lagerbuchse
DE502006006589D1 (de) Teils
ATE485368T1 (de) Hiv - impfung
DE502006004302D1 (de) Verschlusskappe
DE502006003147D1 (de) Verbundgußplatte
DE502006001004D1 (de) Hydrolager
DE102005052834B8 (de) Punktschweißklebverbindung
DE502006003210D1 (de) Nohydrogenpolysiloxanen
AT501523A3 (de) Estrich
DE102006033170A8 (de) Einfassnähmaschine
DE502006000445D1 (de) Mulchmähdeck
DE502006006199D1 (de) Rzuständen